An observational study in Migraine, sponsored by National and Kapodistrian University of Athens. Not yet recruiting at 1 site in Greece. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by National and Kapodistrian University of Athens · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Migraine Disorders with a site in Greece — 3 open to participants now, 3 under way, none of them phase 3. Migraine Disorders · Greece.
Among the 13 studies in Migraine Disorders with a site in Greece, this one is one of 3 that started in 2026, is one of 6 observational ones, and was the 12th registered.
1,657 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.
Browse Migraine Disorders studies →3 of the 13 studies in Migraine Disorders with a site in Greece are open now. Recruiting first, the newest first:
National and Kapodistrian University of Athens · Sites in Greece
Ages 18–70
National and Kapodistrian University of Athens · Sites in Greece
Ages 18–70
A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 130 is close to the median of 137 across 331 observational studies indexed under Migraine Disorders.
Median enrollment 477 across the 7 interventional studies, 102 across the 6 observational. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 13 have an industry lead sponsor. The 8 most frequent:
National and Kapodistrian University of Athens is the lead sponsor of 176 studies on the registry; 54 are open to participants now.
National and Kapodistrian University of Athens has 5 studies filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
3 of the studies in Migraine Disorders with a site in Greece that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07843745National and Kapodistrian University of AthensAssessment of Head Awareness in Patients With Migraine in the Greek Population | 2027-06-01 |
| NCT07847554National and Kapodistrian University of AthensValidity and Reliability of the Greek WPAI:Migraine | 2027-06-01 |
| NCT07847528National and Kapodistrian University of AthensValidity and Reliability of the Greek Pain Catastrophizing Scale | 2027-06-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 13 studies in Migraine Disorders with a site in Greece, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Migraine is a common neurological disorder that can significantly affect daily activities, quality of life, and emotional well-being. How individuals think and feel about pain may also influence their experience of migraine. Pain catastrophizing refers to an exaggerated negative response to pain, including persistent worry about pain and feelings of helplessness.
The Pain Catastrophizing Scale (PCS) is a commonly used questionnaire for assessing pain catastrophizing. However, the psychometric properties of the Greek version of the PCS have not been adequately evaluated in people with migraine.
This study aims to evaluate the validity and reliability of the Greek version of the Pain Catastrophizing Scale in patients with migraine. The study will determine whether the Greek PCS can be used as an appropriate tool for assessing pain catastrophizing in the Greek migraine population.
Migraine is a common and highly burdensome neurological disorder that significantly affects patients' quality of life, functioning, and psychosocial well-being [1]. In people with migraine, the overall burden of the disease is determined not only by pain intensity and frequency but also by cognitive and emotional factors related to the perception and management of pain [1,2]. Of particular interest is pain catastrophizing, a maladaptive cognitive state in which the individual perceives pain as excessively threatening, persistently focuses on it, and experiences feelings of helplessness or powerlessness in response to it [3].
The literature has shown that high levels of pain catastrophizing in patients with migraine are associated with greater pain intensity, increased migraine-related disability, and higher levels of anxiety and depression [2-4]. In addition, pain catastrophizing has been reported to play an important role in migraine chronicity and in the overall deterioration of patients' quality of life [5,6].
The Pain Catastrophizing Scale (PCS) is one of the most widely used instruments for assessing pain catastrophizing, and validity and reliability studies have been conducted in many different languages [7-9]. However, available data on the psychometric properties of the Greek version of the PCS in patients with migraine remain limited. A culturally adapted, valid, and reliable Greek version of the scale is particularly important because it may contribute substantially to improving clinical assessment, strengthening research activity, and implementing a comprehensive approach to migraine management.
Therefore, the aim of the present study is the cultural adaptation of the Greek version of the Pain Catastrophizing Scale in patients with migraine and the evaluation of its psychometric properties.
Aim of the study - Hypotheses to be tested The aim of the present study is to examine the validity and reliability of the Greek version of the Pain Catastrophizing Scale in Greek patients with migraine.
Hypotheses:
The study population will consist of adults aged 18-70 years with episodic or chronic migraine diagnosed by a neurologist according to the International Classification of Headache Disorders, 3rd edition (ICHD-3). Participants will be recruited from the Headache Outpatient Clinic of Aeginition Hospital, National and Kapodistrian University of Athens, Greece. Eligible participants must be able to understand, read, write, and speak Greek.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Adults aged 18-70 years with a diagnosis of episodic or chronic migraine according to the International Classification of Headache Disorders, 3rd edition (ICHD-3), who are able to understand, read, write, and speak Greek. Participants will complete the Greek version of the Pain Catastrophizing Scale (PCS) and other study questionnaires for psychometric evaluation. No intervention will be administered.
Pain Catastrophizing Scale
The psychometric properties of the Greek version of the Pain Catastrophizing Scale (PCS) will be evaluated in patients with migraine. The PCS consists of 13 items scored from 0 (never) to 4 (always), with a total score ranging from 0 to 52. Higher scores indicate greater pain catastrophizing. Reliability will be assessed using internal consistency and test-retest reliability.
Time frame: Baseline and 7-14 days after baseline for test-retest reliability.
Migraine Disability Assessment
Migraine-related disability will be assessed using the MIDAS questionnaire. The total score is based on days of activity lost because of headache during the previous 3 months. Higher scores indicate greater migraine-related disability.
Time frame: Baseline
Headache Impact
Headache-related impact on daily functioning and quality of life will be assessed using the HIT-6. Total scores range from 36 to 78, with higher scores indicating greater headache impact.
Time frame: Baseline
Migraine-Specific Quality of Life
Migraine-specific quality of life will be assessed using the 14-item MSQv2.1, which includes Role Function-Restrictive, Role Function-Preventive, and Emotional Function domains. Scores are transformed to a 0-100 scale, with higher scores indicating better migraine-specific quality of life.
Time frame: Baseline
Headache Pain Intensity
Headache pain intensity will be assessed using the VAS, ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity.
Time frame: Baseline
Plan to share: Undecided — The decision regarding the sharing of individual participant data (IPD) has not yet been finalized. Data sharing may be considered upon reasonable request following study completion, subject to participant confidentiality, ethical requirements, and applicable data protection regulations.
Start is estimated for Nov 2026; primary completion for Jun 2027, 7 months later.
Of 132 non-industry observational studies under Migraine Disorders, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 72. This study's planned 7 months is below that.
Counting every sponsor, half of 160 studies reached it within 27 months; a quarter within 13 and three quarters within 63.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Oct 7, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National and Kapodistrian University of Athens →